News
OHRP COVID-19 Guidance (2020)
Updated FDA Guidance for COVID19 (2020)
Notification to Clients: COVID-19 Policy Exception Statement (2020)
FDA Guidance March 2020 Clinical Trial Conduct during COVID-19 (2020)
COVID-19 Instructions for Clients (2020)
Versiti acquires Texas-based Cenetron Central Laboratories and Salus IRB to advance clinical trial capabilities (2019)
Salus IRB Announces Name Change (2014)
Salus IRB Announces Addition of Third Review Board (2013)
Salus IRB Celebrates 25 Years of Trusted Service (2010)
Salus IRB Launches SafeSync Online Submissions (2010)
Salus IRB Announces DHHS Research Oversight (2009)
Salus IRB Receives Full Accreditation from AAHRPP (2009)
Salus IRB Announces Launch of GlobeSync Virtual Workspace (2009)
Cenetron Diagnostics Announces the Acquisition of Salus IRB (2008)
About Us
Our Boards
Your Salus Team
Mission and Values
Compliance Statement
Affiliations
News
Submission Forms >>
Review & Response Times >>
Request IRB Roster >>
Services
Single Site Research/Local Review
Multi-Site Research/Central IRB Services
Institutional Outsourcing
Global/International Review
Accelerated Phase I
Phase I Oncology
Investigator-Initiated/Sponsored Research
Minimal Risk Research
IRB Exempt Determinations
Other Services
Getting Started >>
Submission Forms >>
Contact Us >>
Why Salus
Getting Started >>
Submission Forms >>
Review & Response Times >>
Getting Started
Submission Forms
Template Study Documents
Review & Response Times
Resources
Training
Contact Us >>
Client Feedback Survey >>
Sponsors/CROs
Reporting Responsibilities
Resources
Training
Getting Started >>
Submission Forms >>
Review & Response Times >>
Investigators
Reporting Responsibilities
Resources
Training
Getting Started >>
Submission Forms >>
Review & Response Times >>
Research Participants
Participant Inquiries
Frequently Asked Questions
Resources
Resources
Contact Us
Client Feedback Survey
Salus IRB Team Member Recognition
855.300.0815